FREQ - Frequency Therapeutics, Inc.
Frequency Therapeutics, Inc.
75 Hayden Avenue
Suite 300
Lexington, MA 02421
United States
781 315 4600
https://www.frequencytx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 46
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David L. Lucchino | Co-Founder, Pres, CEO & Director | 1.02M | N/A | 1970 |
| Dr. Christopher R. Loose Ph.D. | Co-Founder & Chief Scientific Officer | 687.73k | N/A | 1981 |
| Mr. Richard J. Mitrano | VP of Fin. & Operations | N/A | N/A | 1971 |
| Mr. James P. Abely | Associate Gen. Counsel & Sec. | N/A | N/A | N/A |
| Dr. Dana C. Hilt M.D. | Chief Medical Officer (acting) | N/A | N/A | 1953 |
| Dr. John L. LaMattina Ph.D. | Sr. Advisor & Member of PCA Regenerative Medicine Advisory Board | N/A | N/A | 1950 |
| Dr. Quentin McCubbin Ph.D. | Chief Manufacturing Officer | N/A | N/A | 1970 |
Description
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Corporate Governance
Frequency Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2023 is 10. The pillar scores are Audit: 3; Board: 10; Shareholder Rights: 8; Compensation: 10.
